Pfizer to Host Investor Webcast at Jefferies Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 27 2026
0mins
Source: Newsfilter
- Webcast Announcement: Pfizer Inc. will host a webcast on June 3, 2026, at 2:00 p.m. EDT during the Jefferies Global Healthcare Conference in New York, featuring CEO Albert Bourla, which is expected to draw significant investor and public interest.
- Access Information: Investors can visit Pfizer's website to access the webcast, with registration details available starting today, ensuring participants can smoothly listen to and view this important discussion.
- Replay and Transcript: The transcript and replay of the webcast will be made available on Pfizer's website within 24 hours after the live discussion, accessible for at least 90 days, allowing investors who could not attend live to catch up on the information.
- Company Mission and Vision: Pfizer emphasizes its commitment to applying science and global resources to provide innovative therapies, highlighting its standards for quality, safety, and value in healthcare product development, showcasing its responsibility as a leading biopharmaceutical company.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 25.690
Low
24.00
Averages
28.56
High
35.00
Current: 25.690
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pfizer's 6.7% Dividend Yield Analysis
- Dividend Yield Comparison: Pfizer's 6.7% dividend yield stands out against the S&P 500's 1.1% and the pharmaceutical industry's average of 1.7%, making it particularly attractive to dividend investors, despite the looming risk of a dividend cut.
- Management's Dividend Policy: Pfizer's management has clearly stated its intention to maintain the dividend, aligning this decision with its strategy of investing in R&D and launching new products, which underscores the company's commitment to shareholder interests amid current business challenges.
- Patent Expiration Risks: The company faces upcoming patent expirations that could lead to revenue declines, and it lacks new drugs to offset this impact; however, Pfizer's swift acquisition of a promising GLP-1 candidate demonstrates its ability to adapt quickly.
- Financial Health Status: While Pfizer's 130% payout ratio raises concerns, its cash dividend payout ratio is just above 100%, and its debt-to-equity ratio of 0.7 is lower than its competitors, indicating that the company can still sustain dividend payments in the short term.
See More
Pfizer Advances Berobenatide in Phase 2b Trials for Obesity Management
- Clinical Trial Results: Pfizer presented Phase 2b study results for berobenatide at the 86th Scientific Sessions of the American Diabetes Association, showing a nearly 16% non-placebo-adjusted weight loss at 32 weeks with a 2.4 mg weekly dose, indicating the drug's potential in obesity management.
- Future Research Plans: Pfizer plans to initiate 10 Phase 3 studies in 2026 targeting obesity and related comorbidities, such as knee osteoarthritis and obstructive sleep apnea, which will significantly bolster its market position in obesity treatment.
- Dosing Strategy: The Phase 2b studies demonstrated continuous weight loss across all selected doses while maintaining a tolerable profile during the transition from weekly to monthly dosing, laying a solid foundation for future clinical applications.
- Patient-Friendly Delivery: With an injection volume of only 0.5 mL, the drug offers a convenient administration experience, which may enhance patient adherence and lead to better long-term outcomes in obesity treatment.
See More
Pfizer Partners with Chinese Biopharma Innovent for Growth
- Ongoing Revenue Pressure: Pfizer's net income is under pressure, likely to persist, with revenue plummeting from over $100 billion in 2022 to only $62.6 billion last year, reflecting a sharp decline in demand for its COVID-19 vaccine and treatment, which adversely affects overall financial performance.
- Patent Cliff Approaching: Major drugs like Eliquis and Ibrance are set to lose patent protection next year, with these three drugs projected to account for over $20 billion of revenue in 2025, creating uncertainty for the company's future revenue growth.
- Strategic Partnership Agreement: Pfizer's $10.5 billion deal with Chinese biopharma Innovent Biologics requires only a $650 million upfront payment, with the remaining funds contingent on achieving developmental and commercialization milestones, thus incentivizing both companies to collaborate effectively and reducing Pfizer's financial risk.
- Future Growth Potential: Pfizer plans to initiate around 20 pivotal drug trials in 2023, with the CEO stating that the partnership with Innovent provides an opportunity for future cash flow, aiding in maintaining dividend payments amidst a looming $60.5 billion long-term debt burden.
See More
Pfizer Partners with Innovent Biologics in $10.5 Billion Deal
- Revenue Recovery Challenge: Pfizer has not restored its revenue post-COVID-19, reporting $62.6 billion in 2022, a significant drop from over $100 billion in 2021, indicating a sharp decline in demand for its vaccines and treatments, which may impact its future dividend payments.
- Patent Expiration Risks: Several of Pfizer's top-selling drugs, including Eliquis and Ibrance, are set to lose patent protection next year, with these three drugs alone expected to contribute over $20 billion in revenue by 2025, putting pressure on the company's future revenue growth.
- Strategic Partnership Benefits: The partnership with Innovent Biologics, valued at $10.5 billion, requires only a $650 million upfront payment, with subsequent payments tied to developmental and commercialization milestones, reducing financial risk and incentivizing both parties to excel.
- Future Growth Potential: Pfizer plans to initiate around 20 pivotal drug trials in 2023, with the CEO stating that the collaboration with Innovent will provide opportunities for future cash flow, helping maintain dividend payments amid a looming $60.5 billion long-term debt burden.
See More
Pfizer Partners with Innovent Biologics in $10.5 Billion Deal
- Revenue Decline Pressure: Pfizer's revenue plummeted from over $100 billion in 2022 to $62.6 billion in 2023, reflecting a significant drop in demand for its COVID-19 vaccine and treatment, compelling the company to seek new revenue streams to maintain its dividend payments.
- Patent Cliff Challenge: Key drugs like Eliquis and Ibrance are set to lose patent protection next year, potentially impacting over $20 billion of revenue in 2025, thereby increasing financial pressure on the company moving forward.
- Strategic Partnership Opportunity: The $10.5 billion deal with Innovent Biologics requires only a $650 million upfront payment, with subsequent payments tied to drug development and commercialization milestones, which mitigates Pfizer's financial risk while enhancing future cash flow potential.
- Market Expansion Advantage: This collaboration involves co-developing 12 cancer drugs, leveraging Innovent's access to the Chinese market, which allows Pfizer to expand its global market reach and potentially unlock new growth opportunities.
See More
Analysis of Pfizer's Dividend Policy Stability
- Dividend Yield Comparison: Pfizer's dividend yield stands at 6.7%, significantly higher than the S&P 500's 1.1% and the pharmaceutical industry's average of 1.7%, indicating its attractiveness to dividend investors despite potential risks of a dividend cut.
- Management's Dividend Commitment: Pfizer's management explicitly stated in its Q1 earnings report that maintaining the dividend is one of its strategic goals, reflecting the company's commitment to shareholder interests and its intention to support current dividend payments during challenging times.
- Patent Expiration Challenges: Pfizer faces revenue reduction due to upcoming patent expirations and lacks new drugs to offset this impact, which, while common in the pharmaceutical sector, necessitates close monitoring of its potential effects on future revenues.
- Financial Health Status: Pfizer's cash dividend payout ratio is slightly above 100%, and its debt-to-equity ratio is 0.7, lower than its competitor Eli Lilly's 1.4, indicating Pfizer's financial flexibility in managing dividend payments, although attention must still be paid to its new drug development progress.
See More
Pfizer's 6.7% Dividend Yield Analysis
- Dividend Yield Comparison: Pfizer's 6.7% dividend yield stands out against the S&P 500's 1.1% and the pharmaceutical industry's average of 1.7%, making it particularly attractive to dividend investors, despite the looming risk of a dividend cut.
- Management's Dividend Policy: Pfizer's management has clearly stated its intention to maintain the dividend, aligning this decision with its strategy of investing in R&D and launching new products, which underscores the company's commitment to shareholder interests amid current business challenges.
- Patent Expiration Risks: The company faces upcoming patent expirations that could lead to revenue declines, and it lacks new drugs to offset this impact; however, Pfizer's swift acquisition of a promising GLP-1 candidate demonstrates its ability to adapt quickly.
- Financial Health Status: While Pfizer's 130% payout ratio raises concerns, its cash dividend payout ratio is just above 100%, and its debt-to-equity ratio of 0.7 is lower than its competitors, indicating that the company can still sustain dividend payments in the short term.
See More
Pfizer Advances Berobenatide in Phase 2b Trials for Obesity Management
- Clinical Trial Results: Pfizer presented Phase 2b study results for berobenatide at the 86th Scientific Sessions of the American Diabetes Association, showing a nearly 16% non-placebo-adjusted weight loss at 32 weeks with a 2.4 mg weekly dose, indicating the drug's potential in obesity management.
- Future Research Plans: Pfizer plans to initiate 10 Phase 3 studies in 2026 targeting obesity and related comorbidities, such as knee osteoarthritis and obstructive sleep apnea, which will significantly bolster its market position in obesity treatment.
- Dosing Strategy: The Phase 2b studies demonstrated continuous weight loss across all selected doses while maintaining a tolerable profile during the transition from weekly to monthly dosing, laying a solid foundation for future clinical applications.
- Patient-Friendly Delivery: With an injection volume of only 0.5 mL, the drug offers a convenient administration experience, which may enhance patient adherence and lead to better long-term outcomes in obesity treatment.
See More
Pfizer Partners with Chinese Biopharma Innovent for Growth
- Ongoing Revenue Pressure: Pfizer's net income is under pressure, likely to persist, with revenue plummeting from over $100 billion in 2022 to only $62.6 billion last year, reflecting a sharp decline in demand for its COVID-19 vaccine and treatment, which adversely affects overall financial performance.
- Patent Cliff Approaching: Major drugs like Eliquis and Ibrance are set to lose patent protection next year, with these three drugs projected to account for over $20 billion of revenue in 2025, creating uncertainty for the company's future revenue growth.
- Strategic Partnership Agreement: Pfizer's $10.5 billion deal with Chinese biopharma Innovent Biologics requires only a $650 million upfront payment, with the remaining funds contingent on achieving developmental and commercialization milestones, thus incentivizing both companies to collaborate effectively and reducing Pfizer's financial risk.
- Future Growth Potential: Pfizer plans to initiate around 20 pivotal drug trials in 2023, with the CEO stating that the partnership with Innovent provides an opportunity for future cash flow, aiding in maintaining dividend payments amidst a looming $60.5 billion long-term debt burden.
See More
Pfizer Partners with Innovent Biologics in $10.5 Billion Deal
- Revenue Recovery Challenge: Pfizer has not restored its revenue post-COVID-19, reporting $62.6 billion in 2022, a significant drop from over $100 billion in 2021, indicating a sharp decline in demand for its vaccines and treatments, which may impact its future dividend payments.
- Patent Expiration Risks: Several of Pfizer's top-selling drugs, including Eliquis and Ibrance, are set to lose patent protection next year, with these three drugs alone expected to contribute over $20 billion in revenue by 2025, putting pressure on the company's future revenue growth.
- Strategic Partnership Benefits: The partnership with Innovent Biologics, valued at $10.5 billion, requires only a $650 million upfront payment, with subsequent payments tied to developmental and commercialization milestones, reducing financial risk and incentivizing both parties to excel.
- Future Growth Potential: Pfizer plans to initiate around 20 pivotal drug trials in 2023, with the CEO stating that the collaboration with Innovent will provide opportunities for future cash flow, helping maintain dividend payments amid a looming $60.5 billion long-term debt burden.
See More
Pfizer Partners with Innovent Biologics in $10.5 Billion Deal
- Revenue Decline Pressure: Pfizer's revenue plummeted from over $100 billion in 2022 to $62.6 billion in 2023, reflecting a significant drop in demand for its COVID-19 vaccine and treatment, compelling the company to seek new revenue streams to maintain its dividend payments.
- Patent Cliff Challenge: Key drugs like Eliquis and Ibrance are set to lose patent protection next year, potentially impacting over $20 billion of revenue in 2025, thereby increasing financial pressure on the company moving forward.
- Strategic Partnership Opportunity: The $10.5 billion deal with Innovent Biologics requires only a $650 million upfront payment, with subsequent payments tied to drug development and commercialization milestones, which mitigates Pfizer's financial risk while enhancing future cash flow potential.
- Market Expansion Advantage: This collaboration involves co-developing 12 cancer drugs, leveraging Innovent's access to the Chinese market, which allows Pfizer to expand its global market reach and potentially unlock new growth opportunities.
See More
Analysis of Pfizer's Dividend Policy Stability
- Dividend Yield Comparison: Pfizer's dividend yield stands at 6.7%, significantly higher than the S&P 500's 1.1% and the pharmaceutical industry's average of 1.7%, indicating its attractiveness to dividend investors despite potential risks of a dividend cut.
- Management's Dividend Commitment: Pfizer's management explicitly stated in its Q1 earnings report that maintaining the dividend is one of its strategic goals, reflecting the company's commitment to shareholder interests and its intention to support current dividend payments during challenging times.
- Patent Expiration Challenges: Pfizer faces revenue reduction due to upcoming patent expirations and lacks new drugs to offset this impact, which, while common in the pharmaceutical sector, necessitates close monitoring of its potential effects on future revenues.
- Financial Health Status: Pfizer's cash dividend payout ratio is slightly above 100%, and its debt-to-equity ratio is 0.7, lower than its competitor Eli Lilly's 1.4, indicating Pfizer's financial flexibility in managing dividend payments, although attention must still be paid to its new drug development progress.
See More
